JP2002500629A - テトラアザ−またはN2S2−錯化剤(complexant)、および放射線診断または放射線治療におけるその使用 - Google Patents
テトラアザ−またはN2S2−錯化剤(complexant)、および放射線診断または放射線治療におけるその使用Info
- Publication number
- JP2002500629A JP2002500629A JP54176898A JP54176898A JP2002500629A JP 2002500629 A JP2002500629 A JP 2002500629A JP 54176898 A JP54176898 A JP 54176898A JP 54176898 A JP54176898 A JP 54176898A JP 2002500629 A JP2002500629 A JP 2002500629A
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- nitrogen
- independently
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/33—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
- C07C323/34—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a mercapto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/10—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
- C07F9/3817—Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の式の化合物であって: ここで: n=1であり; R1およびR2は、独立して、水素、=O(但し、両方ともが=Oではない)、-(CH2)m -Z(ここで、mは0〜10であり、Zは結合基または標的化部分を表す)、および- (CH2)m-W(ここで、mは0〜10であり、Wは加水分解可能な基を表す)から選択さ れるか、またはR1およびR2は一緒になって、環式無水物もしくはベンゼン環を形 成し; R3は、水素、低級アルキル、アルコキシ、ハロゲン、ヒドロキシル、ニトロ、 -(CH2)m-Zまたは-(CH2)m-Wであり; R4およびR5は、該環の1つ以上の位置で結合し、そして独立して、水素、低級 アルキル、アルコキシ、ハロゲン、ヒドロキシル、ニトロ、-(CH2)m-Zおよび-(C H2)m-Wから選択され; R6およびR7は、独立して、水素(但し、両方ともが水素ではない)、低級アル キル、アルコキシ、ハロゲン、ヒドロキシル、ニトロ、-(CH2)m-Z、-(CH2)m-Wお よび から選択され、 ここで、Qは、金属イオンと配位し得る多価酸官能基を表し、p=0〜1であり ;R12およびR13は、独立して、水素、ヒドロキシル、カルボキシル、ホスホン酸 、および1〜10個の炭素原子を有する炭化水素基、および該酸基の生理学的に受 容可能な塩から選択され; X、X'、YおよびY'は、独立して、炭素、窒素、酸素およびイオウから選択され て、独立して、5または6員芳香環を形成し、ここで、残りの環原子が炭素であ り; AおよびA'は、独立して、イオウおよび窒素から選択され、ここでイオウは、 水素またはイオウ保護基を有するか、またはここでAおよびA'は両方ともイオウ であり、AおよびA'は結合によって互いに連結され得;ここで、窒素は水素を有 し得るか;またはここで、AまたはA'は窒素であり、AはR8もしくはR10または両 方を有し得、かつA'はR9もしくはR11または両方を有し得、ここでR8、R9、R10お よびR11は、独立して、低級アルキル、アルコキシ、ハロゲン、ヒドロキシル、 ニトロ、-(CH2)m-Z、-(CH2)m-Wおよび から選択されるか;またはR8およびR10は連結して環式無水物を形成し得るか、 もしくはR9およびR11は連結して環式無水物を形成し得るか;またはAおよびA'が 両方とも窒素である場合、R10およびR11は連結してTを形成し得、ここでTは、 であり、nは0〜1であり、R1'およびR2'は、独立して、水素、=O(但し、両方 ともが=Oではない)、-(CH2)m-Zから選択されるか、またはR1'およびR2'は、一 緒になって、環式無水物もしくはベンゼン環を形成し;R3'は、水素、低級アル キル、アルコキシ、ハロゲン、ヒドロキシル、ニトロ、-(CH2)m-Zもしくは-(CH2 )m-Wであり;そして 少なくとも1つのZ、WまたはQを有する、化合物。 2.請求項1に記載の化合物であって、ここで: R1およびR2は、独立して、水素、=O(両方ともが=Oではない)、および-(CH2)m -Z(ここでmは0〜10であり、そしてZは結合基または標的化部分を表す)から 選択されるか、またはR1およびR2は、一緒になって、環式無水物もしくはベンゼ ン環を形成し; R3は、水素、低級アルキル、アルコキシ、ハロゲン、ヒドロキシル、ニトロま たは-(CH2)m-Zであり; R4およびR5は、該環の1つ以上の位置で結合し、そして独立して、水素、低級 アルキル、アルコキシ、ハロゲン、ヒドロキシル、ニトロおよび-(CH2)m-Zから 選択され; R6およびR7は、独立して、水素(但し、両方ともが水素ではない)、低級アル キル、アルコキシ、ハロゲン、ヒドロキシル、ニトロおよび-(CH2)m-Z、または から選択され; X、X'、YおよびY'は、独立して、炭素、窒素およびイオウから選択されて、5 または6員芳香環を形成し、ここで、残りの環原子が炭素であり; AおよびA'は、独立して、イオウおよび窒素から選択され、ここでイオウは、 水素またはイオウ保護基を有するか、またはここでAおよびA'は両方ともイオウ であり、AおよびA'は結合によって互いに連結され得;ここで、窒素は水素を有 し得るか;またはここで、AまたはA'は窒素であり、AはR8もしくはR10または両 方を有し得、かつA'はR9もしくはR11または両方を有し得、ここでR8、R9、R10お よびR11は、独立して、低級アルキル、アルコキシ、ハロゲン、ヒドロキシル、 ニトロ、-(CH2)m-Zおよび から選択されるか;またはR8およびR10は連結して環式無水物を形成し得るか、 もしくはR9およびR11は連結して環式無水物を形成し得るか;またはAおよびA'が 両方とも窒素である場合、R10およびR11は連結してTを形成し得、ここでTは、 であり、nは0〜1であり、R1'およびR2'は、独立して、水素、=O(但し、両方 ともが=Oではない)、および-(CH2)m-Zから選択されるか;またはR1'およびR2' は、一緒になって、環式無水物もしくはベンゼン環を形成し;そしてR3'は、水 素、低級アルキル、アルコキシ、ハロゲン、ヒドロキシル、ニトロもしくは-(CH2 )m-Zであり;そして 少なくとも1つのZまたはQを有する、化合物。 3.請求項2に記載の化合物であって、ここでn=1であり;R1、R2、R3は水素 であり;R4およびR5は、独立して、水素および-(CH2)m-Zから選択され;R6およ びR7は、 であり、ここでp=0であり、R12およびR13は水素であり、Qは金属イオンと配位 し得る多価酸官能基であり;AおよびA'は両方とも窒素であり、ここでAはR8もし くはR10または両方を有し、A'はR9もしくはR11または両方を有し、ここでR8、R9 、R10、R11は であり、ここでQは、独立して、ホスホン酸およびカルボン酸から選択され、p= 0であり、そしてR12およびR13は水素であり;またはR8およびR10は連結して環 式無水物を形成し得るか、もしくはR9およびR11は連結して環式無水物を形成し 得;もしくはR10およびR11は連結してTを形成し得、ここでnは1であり、そして R1'、R2'およびR3'は水素である、化合物。 4.請求項2に記載の化合物であって、ここで、n=0であり;R1およびR2は、 一緒になって、ベンゼン環を形成し;R4およびR5は、独立して、水素および-(CH2 )m-Zから選択され;R6およびR7は、 であり、ここでQは、独立して、ホスホン酸およびカルボン酸から選択され、p= 0であり、そしてR12およびR13は水素であり;AおよびA'は両方とも窒素であり 、そしてR10およびR11は連結してTを形成し、ここでnは0であり、R1'およびR2' は、一緒になって、ベンゼン環を形成し、そしてR8およびR9は、 であり、ここでQは、独立して、ホスホン酸およびカルボン酸から選択され得、p =0であり、そしてR12およびR13は水素である、化合物。 5.請求項2に記載の化合物であって、ここでn=1であり;R1、R2およびR3は 水素であり;R4およびR5は、独立して、水素および-(CH2)m-Zから選択され;R6 およびR7は、 であり、ここで、Qは、独立して、ホスホン酸およびカルボン酸から選択され、p =0であり、そしてR12およびR13は水素であり;AおよびA'は両方とも窒素であ り、R8、R9、R10およびR11は、独立して、-(CH2)m-Z(ここで、mは0〜10であり 、Zは標的化部分である)、ならびにから選択され、ここでQは、独立して、ホスホン酸およびカルボン酸から選択さ れ、p=0であり、そしてR12およびR13は水素であるが、但し、該化合物は、少 なくとも1つのZを有する、化合物。 6.Zが、抗体フラグメント、ビオチンまたはアネキシンから選択される標的化 部分である、請求項5に記載の化合物。 7.請求項1に記載の化合物であって、ここで: R1およびR2は、独立して、水素、=O(但し、両方ともが=Oではない)、および -(CH2)m-W(ここで、mは0〜10であり、Wは加水分解可能な基を表す)から選択 されるか、またはR1およびR2は一緒になって、環式無水物もしくはベンゼン環を 形成し; R3は、水素、低級アルキル、アルコキシ、ハロゲン、ヒドロキシル、ニトロま たは-(CH2)m-Wであり; R4およびR5は、該環の1つ以上の位置で結合し、そして独立して、水素、低級 アルキル、アルコキシ、ハロゲン、ヒドロキシル、ニトロおよび-(CH2)m-Wから 選択され; R6およびR7は、独立して、水素、低級アルキル、アルコキシ、ハロゲン、ヒド ロキシル、ニトロ、-(CH2)m-Wおよび から選択され; AおよびA'は、独立して、イオウおよび窒素から選択され、ここでイオウは、 水素またはイオウ保護基を有し得るか、またはここでAおよびA'は両方ともイオ ウであり、AおよびA'は結合によって互いに連結され得;ここで、窒素は水素を 有し得るか;またはここで、AまたはA'は窒素であり、AはR8もしくはR10または 両方を有し得、かつA'はR9もしくはR11または両方を有し得、ここでR8、R9、R10 およびR11は、独立して、低級アルキル、アルコキシ、ハロゲン、ヒドロキシル 、ニトロ、-(CH2)m-Wおよび から選択されるか;またはR8およびR10は連結して環式無水物を形成し得るか、 もしくはR9およびR11は連結して環式無水物を形成し得るか;またはAおよびA'が 両方とも窒素である場合、R10およびR11は連結してTを形成し得、ここでTは、 であり、nは0〜1であり、R1'およびR2'は、独立して、水素、=O(但し、両方 ともが=Oではない)、-(CH2)m-W(ここで、mは0〜10であり、Wは加水分解可能 な基を表す)から選択されるか、またはR1'およびR2'は、一緒になって、環式無 水物もしくはベンゼン環を形成し;そしてR3'は、水素、低級アルキル、アルコ キシ、ハロゲン、ヒドロキシル、ニトロおよび-(CH2)m-Wであり;そして 少なくとも1つのWを有する、化合物。 8.請求項7に記載の化合物であって、ここでn=1であり;R1、R2およびR3は 水 素であり;R4およびR5は、独立して、水素および-(CH2)m-Wから選択され;R6お よびR7は、 であり、ここで、Qは、独立して、ホスホン酸およびカルボン酸から選択され、p =0であり、そしてR12およびR13は水素であり;AまたはA'は、独立して、保護 基を含むイオウ、および窒素(但し、AおよびA'の両方がイオウではない)から 選択され得、そして、AまたはA'が窒素である場合、R8およびR10は、独立して、 水素および-(CH2)m-W(ここで、mは1〜10であり、Wは加水分解可能な基を表す )から選択され、但し、両方ともが水素ではない、化合物。 9.Wが、エステル、カルバメートおよびニトリルからなる群から選択される、 請求項8に記載の化合物。 10.X、X'、YおよびY'がすべて炭素である、請求項2から9のいずれか1項に 記載の化合物。 11.実施例IからXIのいずれか1つの表題化合物。 12.放射性核種金属またはその酸化物もしくは窒化物を有する、請求項1から 11のいずれか1項に記載の化合物を含む、錯体。 13.請求項12に記載の錯体であって、前記放射性核種が、テクネチウム、銅 、レニウム、鉛、ビスマス、ルテニウム、ロジウム、イットリウム、サマリウム 、インジウム、金、ガドリニウム、ホルミウム、ルテチウム、イッテルビウムま たはパラジウムの放射性核種である、錯体。 14.前記放射性核種が、テクネチウム、ルテニウム、インジウム、ホルミウム またはイットリウムの放射性核種である、請求項13に記載の錯体。 15.請求項13に記載の錯体であって、前記放射性核種が、64Cu、67Cu、90Y 、97Ru、99mTc、105Rh、109Pd、111In、153Sm、159Gd、166Ho、175Yb、177Lu、1 86 Re、188Re、198Au、199Au、203Pb、212Pbまたは212Biである、錯体。 16.前記放射性核種が、99mTc、186Re、188Re、111In、166Hoまたは90Yである 、請求項14に記載の錯体。 17.診断法または治療法において使用するための、請求項12、13、14、 15または16のいずれか1項に記載の錯体。 18.医薬の製造において使用するための、請求項12、13、14、15また は16のいずれか1項に記載の錯体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/829,533 US6005083A (en) | 1997-03-28 | 1997-03-28 | Bridged aromatic substituted amine ligands with donor atoms |
US08/829,533 | 1997-03-28 | ||
PCT/US1998/005858 WO1998043678A2 (en) | 1997-03-28 | 1998-03-26 | Tetraaza- or n2s2- complexants, and their use in radiodiagnostics or radiotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002500629A true JP2002500629A (ja) | 2002-01-08 |
JP2002500629A5 JP2002500629A5 (ja) | 2005-11-10 |
Family
ID=25254797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54176898A Ceased JP2002500629A (ja) | 1997-03-28 | 1998-03-26 | テトラアザ−またはN2S2−錯化剤(complexant)、および放射線診断または放射線治療におけるその使用 |
Country Status (7)
Country | Link |
---|---|
US (7) | US6005083A (ja) |
EP (2) | EP0971748B1 (ja) |
JP (1) | JP2002500629A (ja) |
CA (1) | CA2284653C (ja) |
DE (1) | DE69837038T2 (ja) |
ES (1) | ES2281927T3 (ja) |
WO (1) | WO1998043678A2 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
US6005083A (en) | 1997-03-28 | 1999-12-21 | Neorx Corporation | Bridged aromatic substituted amine ligands with donor atoms |
US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
BR9912053A (pt) | 1998-07-13 | 2001-04-03 | Univ Texas | Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios |
WO2000002584A2 (en) | 1998-07-13 | 2000-01-20 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
US6239237B1 (en) * | 1999-04-22 | 2001-05-29 | Nova Chemicals (International) S.A. | Group 8, 9 or 10 transition metal catalyst for olefin polymerization |
CA2371728C (en) | 1999-06-11 | 2009-06-02 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
US7094885B2 (en) | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
US7067111B1 (en) | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US6565828B2 (en) * | 2000-04-07 | 2003-05-20 | Bristol-Myers Squibb Company | Macrocyclic chelants for metallopharmaceuticals |
AU2001275210B2 (en) | 2000-06-02 | 2006-09-28 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates |
AU2002249935A1 (en) | 2001-01-08 | 2002-08-19 | Neorx Corporation | Radioactively labelled conjugates of phosphonates |
ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
DE10125258A1 (de) * | 2001-05-23 | 2003-01-09 | November Ag Molekulare Medizin | Verfahren zur Bestimmung des Bindeverhaltens von an Ziel-Molekülen spezifisch bindenden Liganden |
US6890513B2 (en) | 2001-05-25 | 2005-05-10 | Mcmaster University | Metal-carborane complexes for radioimaging and radiotherapy and methods for their preparation |
WO2004002944A1 (en) * | 2002-07-01 | 2004-01-08 | Pharmacia & Upjohn Company | Inhibitors of hcv ns5b polymerase |
US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
US8758723B2 (en) | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2977279A (en) * | 1955-11-29 | 1961-03-28 | Monsanto Chemicals | Copper chelate coordination complexes |
US3027391A (en) * | 1959-08-28 | 1962-03-27 | Norman A Frigerio | Metal phthalocyanines |
US4088747A (en) * | 1975-02-19 | 1978-05-09 | Australian Atomic Energy Commission | Phenolic amino-carboxylic acid radiopharmaceuticals |
DE2616984C3 (de) * | 1976-04-17 | 1981-10-29 | Behringwerke Ag, 3550 Marburg | Verfahren zur Isolierung und Reinigung eines plazentenspezifischen Glycoproteins |
JPS5486602A (en) * | 1977-10-27 | 1979-07-10 | Hoffmann La Roche | Production of purified alpha 1 phetoprotein |
US4293537A (en) * | 1978-09-05 | 1981-10-06 | Wong Dennis W | Novel chemical method of labeling proteins with 99m Tc-Technetium at physiological condition |
JPS567725A (en) * | 1979-06-28 | 1981-01-27 | Daiichi Rajio Isotope Kenkyusho:Kk | Tumor scanning agent |
US4421735A (en) * | 1980-04-17 | 1983-12-20 | The Massachusetts General Hospital | Radiolabeled diagnostic compositions and method for making the same |
US4385046A (en) * | 1980-12-15 | 1983-05-24 | Minnesota Mining And Manufacturing Company | Diagnostic radio-labeled polysaccharide derivatives |
US5648063A (en) * | 1981-07-24 | 1997-07-15 | Schering Aktiengesellschaft | Sterile composition comprising a chelate complex for magnetic resonance imaging |
US4957939A (en) * | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4452774A (en) * | 1982-04-30 | 1984-06-05 | President And Fellows Of Harvard College | Isonitrile radionuclide complexes for labelling and imaging agents |
DE3228503A1 (de) * | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Neues protein (pp(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)7(pfeil abwaerts)), verfahren zu seiner anreicherung und gewinnung sowie seine verwendung |
US4758682A (en) * | 1983-03-17 | 1988-07-19 | California Institute Of Technology | Homogeneous coordination compounds as oxidation catalysts |
DE3315000A1 (de) * | 1983-04-26 | 1984-10-31 | Behringwerke Ag, 3550 Marburg | Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung |
US4515767A (en) * | 1983-06-20 | 1985-05-07 | The Dow Chemical Company | Radioactive metals complexed with phosphonate derivatives of dicyclopentadienebis(methylamine) |
US4673562A (en) * | 1983-08-19 | 1987-06-16 | The Children's Medical Center Corporation | Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents |
US4560548A (en) * | 1984-04-10 | 1985-12-24 | The Dow Chemical Company | Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine |
AU4311085A (en) * | 1984-06-01 | 1985-12-05 | E.I. Du Pont De Nemours And Company | Copper salt and ligand containing composition |
US5064633A (en) * | 1984-06-04 | 1991-11-12 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes, their formulations and use |
US4898724A (en) * | 1984-06-04 | 1990-02-06 | The Dow Chemical Company | Organis amine phosphonic acid complexes for the treatment of calcific tumors |
US5059412A (en) * | 1984-06-04 | 1991-10-22 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors |
US5066478A (en) * | 1984-06-04 | 1991-11-19 | The Dow Chemical Company | Radio labeled organic amine phosphonic acid complexes for the treatment of calcific tumors |
US4963688A (en) * | 1984-07-19 | 1990-10-16 | University Of Florida | Compounds for site-enhanced delivery of radionuclides and uses thereof |
US4963682A (en) * | 1984-07-19 | 1990-10-16 | University Of Florida | Novel radiopharmaceuticals and chelating agents useful in their preparation |
US4722892A (en) * | 1984-08-31 | 1988-02-02 | Meares Claude F | Monoclonal antibodies against metal chelates |
US4897254A (en) * | 1984-09-21 | 1990-01-30 | The Dow Chemical Company | Radioactive compositions for the treatment of calcific tumors |
GB8426845D0 (en) * | 1984-10-24 | 1984-11-28 | Amersham Int Plc | Complexes of technetium-99m |
US5019497A (en) * | 1984-11-09 | 1991-05-28 | Lennart Olsson | Human squamous lung carcinoma cell specific antigens and antibodies |
US4897255A (en) * | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5175343A (en) * | 1985-01-14 | 1992-12-29 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5120526A (en) * | 1985-01-14 | 1992-06-09 | Neorx Corporation | Method of producing metal radionuclide labeled proteins for diagnosis and therapy |
US5037630A (en) * | 1985-01-14 | 1991-08-06 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5242679A (en) * | 1985-01-14 | 1993-09-07 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
EP0194843B1 (en) * | 1985-03-11 | 1993-01-13 | AMERSHAM INTERNATIONAL plc | Complexes of technetium-99m with propylene amine oximes |
US4746505A (en) * | 1985-04-26 | 1988-05-24 | President And Fellows Of Harvard College | Technetium radiodiagnostic fatty acids derived from bisamide bisthiol ligands |
EP0200211A1 (en) * | 1985-05-01 | 1986-11-05 | The Research Foundation Of State University Of New York | Diagnostic radiopharmaceutical compounds |
US5225181A (en) * | 1985-06-07 | 1993-07-06 | The Research Foundation Of State University Of New York | Radiolabeled antiplatelet monoclonal antibody for imaging in-vivo thrombi |
US4831122A (en) * | 1986-01-09 | 1989-05-16 | Regents Of The University Of Minnesota | Radioimmunotoxins |
US5271927A (en) * | 1986-02-13 | 1993-12-21 | Celltech Limited | Antibody conjugates with macrocyclic ligands |
US4732974A (en) * | 1986-03-05 | 1988-03-22 | Mallinckrodt, Inc. | Metal ion labeling of carrier molecules |
US4877868A (en) * | 1986-03-12 | 1989-10-31 | Neorx Corporation | Radionuclide antibody coupling |
US4861869A (en) * | 1986-05-29 | 1989-08-29 | Mallinckrodt, Inc. | Coupling agents for joining radionuclide metal ions with biologically useful proteins |
US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
US4859431A (en) | 1986-11-10 | 1989-08-22 | The Curators Of The University Of Missouri | Rhenium generator system and its preparation and use |
DK172391B1 (da) * | 1986-12-30 | 1998-05-18 | Nihon Mediphysics Co Ltd | Højmolekylær forbindelse til anvendelse som ikke-radioaktiv bærer, radioaktivt mærket højmolekylær forbindelse, fremgangsmåde til fremstilling deraf og fremgangsmåde til forbedret mærkning af en asialoglycoproteinacceptor-dirigerende forbindelse |
US5279811A (en) * | 1987-02-18 | 1994-01-18 | The Du Pont Merck Pharmaceutical Company | Ester-substituted diaminedithiols and radiolabeled complexes thereof |
US5091514A (en) * | 1987-03-26 | 1992-02-25 | Neorx Corporation | Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy |
AR246956A1 (es) * | 1987-05-08 | 1994-10-31 | Salutar Inc | Compuesto quelante, un intermediario para preparar el mismo, y un procedimiento para preparar una composicion de medio de contraste. |
US4853209A (en) * | 1987-05-18 | 1989-08-01 | The Dow Chemical Company | Bone marrow suppressing agents |
WO1989001342A2 (en) * | 1987-08-07 | 1989-02-23 | Mallinckrodt, Inc. | Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound |
DE3880974T2 (de) * | 1987-11-19 | 1993-08-26 | Univ Vanderbilt | Radiojodhaltige benzamide und verfahren zu ihrer verwendung als radiobildende agenzien. |
US5322678A (en) * | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
EP0329184A3 (en) * | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
US5112954A (en) * | 1988-02-26 | 1992-05-12 | Neorx Corporation | Method of enhancing the effect of cytotoxic agents |
US5061641A (en) * | 1988-04-01 | 1991-10-29 | Immunomedics, Inc. | Method for radiolabeling proteins |
US5057301A (en) * | 1988-04-06 | 1991-10-15 | Neorx Corporation | Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents |
US5059541A (en) * | 1988-04-29 | 1991-10-22 | Neorx Corporation | Minimal derivatization of proteins |
US5075099A (en) * | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
CA1340527C (en) * | 1988-05-31 | 1999-05-04 | Lidia Vallarino | Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities |
US5089249A (en) * | 1988-06-10 | 1992-02-18 | Neorx Corporation | Conjugates for bone imaging and bone cancer therapy |
US5002754A (en) * | 1988-06-15 | 1991-03-26 | University Of Cincinnati | Technetium (III/II) imaging agents |
US5071965A (en) * | 1988-07-19 | 1991-12-10 | Mallinckrodt Medical, Inc. | Novel tc-99m complexes |
US5169933A (en) * | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5252713A (en) * | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US4987227A (en) * | 1988-10-21 | 1991-01-22 | The Research Foundation Of State University Of New York | Polyazamacrocycles and their metal complexes |
US4925650A (en) * | 1988-11-16 | 1990-05-15 | Mallinckrodt, Inc. | Technetium -99m complex for examining the renal function |
US4976950A (en) * | 1988-12-19 | 1990-12-11 | The Dow Chemical Company | Bone marrow suppressing agents |
US5053503A (en) * | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
US4959304A (en) * | 1989-05-22 | 1990-09-25 | United States Of America As Represented By The Secretary Of The Navy | Production of monoclonal antibodies to treponema denticola by hybridoma TDIII, IIIBB2 |
US5250666A (en) * | 1989-06-16 | 1993-10-05 | Neorx Corporation | Radionuclide metal chelates for the radiolabeling of proteins |
US5164176A (en) * | 1989-06-16 | 1992-11-17 | Neorx Corporation | Radionuclide metal chelates for the radiolabeling of proteins |
US5021571A (en) * | 1989-06-29 | 1991-06-04 | Associated Universities, Inc. | Cyclohexyl EDTA monoanhydride |
US5334729A (en) * | 1989-06-29 | 1994-08-02 | Associated Universities, Inc. | Stable radiometal antibody immunoconjugates |
DE3930674A1 (de) * | 1989-09-11 | 1991-03-21 | Diagnostikforschung Inst | Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie |
US5053186A (en) | 1989-10-02 | 1991-10-01 | Neorx Corporation | Soluble irradiation targets and methods for the production of radiorhenium |
US5080884A (en) * | 1989-12-12 | 1992-01-14 | Medi-Physics, Inc. | Hydrocarbylphenyl diaminodithiol radionuclide complexes and their use in imaging |
US5026913A (en) * | 1989-12-12 | 1991-06-25 | Medi-Physics, Inc. | Hydrocarbylphenyl diaminodithiol derivatives |
DE69006698T2 (de) * | 1989-12-12 | 1994-05-26 | Amersham Int Plc | Phenyldiaminodithiolderivate. |
US5112953A (en) * | 1989-12-29 | 1992-05-12 | Neorx Corporation | Radiolabeled proteins for diagnostic or therapeutic use |
US5175257A (en) * | 1989-12-29 | 1992-12-29 | Neorx Corporation | Radiolabeled proteins for diagnostic or therapeutic use |
US5079346A (en) * | 1990-05-01 | 1992-01-07 | Trustees Of The University Of Pennsylvania | Gallium-labelled imaging agents |
US5286848A (en) * | 1990-05-07 | 1994-02-15 | Hamamatsu Photonics K.K. | Lanthanide cryptate of trisphenanthroline |
ES2108048T3 (es) * | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5382654A (en) * | 1992-02-05 | 1995-01-17 | Mallinckrodt Medical, Inc. | Radiolabelled peptide compounds |
US5116598A (en) * | 1990-10-29 | 1992-05-26 | Mallinckrodt Medical, Inc. | N4 technetium-99 m complexes for use as radiopharmaceuticals |
US5104638A (en) * | 1990-10-29 | 1992-04-14 | Mallinckrodt Medical, Inc. | Method of making a radiopharmaceutical complex from a kit |
US5243073A (en) * | 1990-12-14 | 1993-09-07 | Mallinckrodt Medical, Inc. | Hexadentate ligands useful in radiographic imaging agents |
US5112595A (en) * | 1990-12-21 | 1992-05-12 | Mallinckrodt Medical, Inc. | 99MTC(III) myocardial imaging agents and method of use |
US5112594A (en) * | 1991-04-04 | 1992-05-12 | Mallinckrodt Medical, Inc. | Kit for preparing a technetium-99m myocardial imaging agent |
US5133956A (en) * | 1991-05-30 | 1992-07-28 | The Dow Chemical Company | Radiolabeled metal-binding protein for the treatment of arthritis |
IT1248361B (it) | 1991-06-28 | 1995-01-05 | Enea | Vettori plasmidici per l'espressione di geni in piante |
WO1994001393A1 (en) * | 1992-07-03 | 1994-01-20 | The Green Cross Corporation | Novel chelating agent, complex compound composed of said agent and metallic atom, and diagnostic agent containing said compound |
US5330737A (en) * | 1991-12-06 | 1994-07-19 | Mallinckrodt Medical, Inc. | Nitrogen-sulfur ligands as opiate receptor drug mimics |
AU665689B2 (en) * | 1991-12-10 | 1996-01-11 | Dow Chemical Company, The | Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents, and processes for their preparation |
US5220000A (en) * | 1992-01-23 | 1993-06-15 | Spyros Theodoropulos | Bifunctional-bis-quinolinols, and their metal chelates |
US5371184A (en) * | 1992-02-05 | 1994-12-06 | Mallinckrodt Medical, Inc. | Radiolabelled peptide compounds |
EP0642357B1 (en) * | 1992-02-05 | 2001-07-25 | Mallinckrodt Inc. | Radiolabelled somatostatin |
US5310536A (en) * | 1992-02-06 | 1994-05-10 | Mallinckrodt Medical, Inc. | Ligands for improving metal chelate formation kinetics |
US5324502A (en) * | 1992-04-02 | 1994-06-28 | Purdue Research Foundation | Radiopharmaceuticals for imaging the heart |
US5319143A (en) * | 1992-07-31 | 1994-06-07 | Polaroid Corporation | Bis(aminoethanethiols) |
US5968477A (en) * | 1994-01-24 | 1999-10-19 | Neorx Corporation | Radiolabeled annexin conjugates with hexose and a chelator |
ZA952485B (en) * | 1994-03-28 | 1995-12-15 | Nycomed Imaging As | Liposomes |
US5476644A (en) * | 1994-04-13 | 1995-12-19 | Sterling Winthrop Inc. | Cyclic triamine chelating agents |
CA2190727C (en) * | 1994-05-19 | 2006-07-18 | Sudhakar Kasina | Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging |
WO1995032192A1 (en) * | 1994-05-19 | 1995-11-30 | Neorx Corporation | Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging |
US5508458A (en) * | 1995-05-26 | 1996-04-16 | Hoechst Celanese Corporation | Chiral catalysts and processes for preparing the same |
CA2225453C (en) * | 1995-06-26 | 2004-12-14 | Concat, Ltd. | Compounds with chelation affinity and selectivity for first transition series elements, and their use in medical therapy and diagnosis |
US6005083A (en) * | 1997-03-28 | 1999-12-21 | Neorx Corporation | Bridged aromatic substituted amine ligands with donor atoms |
-
1997
- 1997-03-28 US US08/829,533 patent/US6005083A/en not_active Expired - Lifetime
-
1998
- 1998-03-26 ES ES98912032T patent/ES2281927T3/es not_active Expired - Lifetime
- 1998-03-26 EP EP98912032A patent/EP0971748B1/en not_active Expired - Lifetime
- 1998-03-26 EP EP07001523A patent/EP1813607A3/en not_active Withdrawn
- 1998-03-26 CA CA002284653A patent/CA2284653C/en not_active Expired - Fee Related
- 1998-03-26 WO PCT/US1998/005858 patent/WO1998043678A2/en active IP Right Grant
- 1998-03-26 DE DE69837038T patent/DE69837038T2/de not_active Expired - Lifetime
- 1998-03-26 JP JP54176898A patent/JP2002500629A/ja not_active Ceased
-
1999
- 1999-05-12 US US09/310,900 patent/US6177551B1/en not_active Expired - Fee Related
- 1999-05-12 US US09/310,455 patent/US6187910B1/en not_active Expired - Fee Related
-
2000
- 2000-11-28 US US09/724,834 patent/US6528627B1/en not_active Expired - Fee Related
-
2003
- 2003-01-17 US US10/346,311 patent/US6936700B2/en not_active Expired - Fee Related
-
2005
- 2005-02-18 US US11/061,110 patent/US7268220B2/en not_active Expired - Fee Related
-
2007
- 2007-09-04 US US11/849,769 patent/US7674886B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69837038D1 (de) | 2007-03-22 |
US6187910B1 (en) | 2001-02-13 |
EP1813607A3 (en) | 2007-08-15 |
CA2284653A1 (en) | 1998-10-08 |
CA2284653C (en) | 2008-07-29 |
US6528627B1 (en) | 2003-03-04 |
US6177551B1 (en) | 2001-01-23 |
WO1998043678A3 (en) | 1999-03-04 |
US20050276754A1 (en) | 2005-12-15 |
EP1813607A2 (en) | 2007-08-01 |
US20030158393A1 (en) | 2003-08-21 |
EP0971748B1 (en) | 2007-02-07 |
US6005083A (en) | 1999-12-21 |
US7674886B2 (en) | 2010-03-09 |
US20080227961A1 (en) | 2008-09-18 |
DE69837038T2 (de) | 2007-07-12 |
US6936700B2 (en) | 2005-08-30 |
ES2281927T3 (es) | 2007-10-01 |
EP0971748A2 (en) | 2000-01-19 |
WO1998043678B1 (en) | 1999-04-01 |
WO1998043678A2 (en) | 1998-10-08 |
US7268220B2 (en) | 2007-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7674886B2 (en) | Bridged aromatic substituted amine ligands with donor atoms | |
US5175343A (en) | Metal radionuclide labeled proteins for diagnosis and therapy | |
US4897255A (en) | Metal radionuclide labeled proteins for diagnosis and therapy | |
US5202451A (en) | Anchimeric radiometal chelating compounds | |
US5037630A (en) | Metal radionuclide labeled proteins for diagnosis and therapy | |
US5242679A (en) | Metal radionuclide labeled proteins for diagnosis and therapy | |
EP4095130A1 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
JPH075527B2 (ja) | 二官能性dtpa型リガンド | |
US5756685A (en) | Protein conjugate containing metal radionuclide labeled proteins | |
KR0153468B1 (ko) | 오르토 결합 작용기를 갖는 킬란트 및 그의 착물 | |
EP2637705B1 (en) | Conjugates and their uses in molecular imaging | |
US5120526A (en) | Method of producing metal radionuclide labeled proteins for diagnosis and therapy | |
Joaqui-Joaqui et al. | Catechol-based functionalizable ligands for gallium-68 positron emission tomography imaging | |
HUT73665A (en) | Bifunctional-chelating agents braked with calcogene atoms, pharmaceutical compositions containing them , and use of these compositions in radio- diagnosis and radiotherapy | |
JP3863178B2 (ja) | 画像診断用の芳香族アミンで置換された橋かけ窒素および硫黄供与体原子配位子 | |
JPH09512251A (ja) | 金属含有ステロイド模擬体およびその製造に有用なリガンド | |
JP2023545213A (ja) | 切断型エバンスブルー修飾線維芽細胞活性化タンパク質阻害剤及びその調製方法と応用 | |
JOUHARI et al. | An improved synthesis and preliminary biodistribution study of a Technetium-99m-labeled 2-amino-2-deoxy (thioacetyl)-D-glucose complex ([99mTc]-TA-DG) as a tumor imaging agent | |
CN111909149A (zh) | 用于癌症诊断的分子探针,用途以及合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050325 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070612 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070903 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071015 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071009 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071119 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080123 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080507 |